Serologia do VHB/VHC/HIV + avaliação dentária pré-bisfosfonato/denosumab + genotipagem da DPD...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | RF-BREAST-INFECTION-SCREENING |
|---|---|
| Tipo | Sinal de alerta |
| Estado | pending_clinical_signoff |
| Doenças | DIS-BREAST |
| Fontes | SRC-ESMO-BREAST-EARLY-2024 SRC-NCCN-BREAST-2025 |
Origem da bandeira vermelha
| Definição | HBV/HCV/HIV serology + dental evaluation pre-bisphosphonate/denosumab + DPYD genotyping for capecitabine-containing regimens (EU practice). |
|---|---|
| Direcção clínica | investigar |
| Categoria | rastreamento de infecções |
Lógica de Desencadeamento
{
"any_of": [
{
"finding": "hbsag",
"value": "positive"
},
{
"finding": "dental_clearance_pending",
"value": true
},
{
"finding": "dpyd_deficient",
"value": true
}
],
"type": "composite_clinical"
}
Notas
Cross-disease HBV reactivation handled by RF-UNIVERSAL-HBV-REACTIVATION- RISK. DPYD deficiency screening unique to fluoropyrimidine-containing regimens; severe / fatal toxicity in homozygous deficient patients — EU/EMA-recommended pre-test.
Usado por
Indicação
IND-BREAST-BRCA-MET-TALAZOPARIB- IND-BREAST-BRCA-MET-TALAZOPARIBIND-BREAST-BRCA-POS-MET-PARPI- IND-BREAST-BRCA-POS-MET-PARPIIND-BREAST-HER2-LOW-2L-DATO-DXD- IND-BREAST-HER2-LOW-2L-DATO-DXDIND-BREAST-HER2-POS-3L-TUCATINIB- IND-BREAST-HER2-POS-3L-TUCATINIBIND-BREAST-HER2-POS-EARLY-NEOADJUVANT- IND-BREAST-HER2-POS-EARLY-NEOADJUVANTIND-BREAST-HER2-POS-MAINT-TRAST- IND-BREAST-HER2-POS-MAINT-TRASTIND-BREAST-HER2-POS-MET-1L-THP- IND-BREAST-HER2-POS-MET-1L-THPIND-BREAST-HER2-POS-MET-2L-TDXD- IND-BREAST-HER2-POS-MET-2L-TDXDIND-BREAST-HR-POS-1L-INAVOLISIB- IND-BREAST-HR-POS-1L-INAVOLISIBIND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB- IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIBIND-BREAST-HR-POS-2L-DATO-DXD- IND-BREAST-HR-POS-2L-DATO-DXDIND-BREAST-HR-POS-2L-ESR1-ELACESTRANT- IND-BREAST-HR-POS-2L-ESR1-ELACESTRANTIND-BREAST-HR-POS-2L-FUL-EVEROLIMUS- IND-BREAST-HR-POS-2L-FUL-EVEROLIMUSIND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB- IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIBIND-BREAST-HR-POS-2L-T-DXD-HER2-LOW- IND-BREAST-HR-POS-2L-T-DXD-HER2-LOWIND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT- IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKTIND-BREAST-HR-POS-MAINT-CDK46I- IND-BREAST-HR-POS-MAINT-CDK46IIND-BREAST-HR-POS-MET-1L-CDKI- IND-BREAST-HR-POS-MET-1L-CDKIIND-BREAST-TNBC-2L-BRCA-OLAPARIB- IND-BREAST-TNBC-2L-BRCA-OLAPARIBIND-BREAST-TNBC-2L-BRCA-TALAZOPARIB- IND-BREAST-TNBC-2L-BRCA-TALAZOPARIBIND-BREAST-TNBC-2L-DATO-DXD- IND-BREAST-TNBC-2L-DATO-DXDIND-BREAST-TNBC-2L-SACITUZUMAB- IND-BREAST-TNBC-2L-SACITUZUMABIND-BREAST-TNBC-2L-T-DXD-HER2-LOW- IND-BREAST-TNBC-2L-T-DXD-HER2-LOWIND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD- IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXDIND-BREAST-TNBC-EARLY-NEOADJUVANT- IND-BREAST-TNBC-EARLY-NEOADJUVANTIND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO- IND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO